H
igher levels of physical activity (PA) in healthy subjects have been associated with a lower risk of adverse cardiovascular outcomes, including lower incident heart failure (HF), with a well-described dose-response relationship. [1] [2] [3] [4] [5] [6] The impact of exercise is less clear in those with HF with preserved ejection fraction (HFpEF). With exercise training, several studies have demonstrated improvement in measures of cardiorespiratory fitness (peak oxygen uptake) and quality of life but uncertain benefit in clinical outcomes such as HF hospitalization and mortality. [7] [8] [9] [10] [11] [12] [13] [14] [15] Both pharmacological trials and exercise training interventions have yet to demonstrate a mortality benefit in this population. [16] [17] [18] [19] Moreover, the impact of PA on adverse cardiovascular outcomes has not been examined in a large cohort of patients with HFpEF. 20, 21 We hypothesized that poor PA would be associated with subsequent adverse cardiovascular outcomes in patients with HFpEF and tested this hypothesis in participants enrolled in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). In this report, we describe the spectrum of baseline PA in this HFpEF cohort, their characteristics according to level of PA, and the relationship of PA with adverse cardiovascular outcomes in patients with HFpEF.
METHODS

Study Design and Population
The study population comprised the 1751 subjects enrolled in the Americas region of the TOPCAT trial (United States, Canada, Brazil, Argentina). We focused on patients enrolled in the Americas region because of significant differences in population characteristics and outcomes by region. 22 The TOPCAT trial was designed to determine whether treatment with spironolactone would reduce morbidity and mortality in patients with HFpEF. Eligible subjects included those with symptomatic HF and left ventricular (LV) ejection fraction (LVEF) ≥45% who had either a hospitalization for HF within 12 months or elevated brain natriuretic peptide (BNP; BNP ≥100 pg/mL or N-terminal pro-BNP ≥360 pg/mL) within 60 days before randomization. Participants were randomized to spironolactone or placebo and stratified by entry criteria of hospitalization or natriuretic peptides. Additional details of the study design and exclusion criteria have been published, and the trial was conducted with the approval of local institutional review boards. 19 All patients provided written informed consent. The primary outcome was defined as the composite of death resulting from a cardiovascular cause, aborted cardiac arrest, or HF hospitalization. Secondary outcomes included the individual components in addition to myocardial infarction and stroke, all centrally adjudicated. All deaths and all hospitalizations were also defined as secondary outcomes of both the original TOPCAT trial and this analysis. An echocardiographic substudy was also conducted and represents a subset of baseline studies performed before randomization; the echocardiographic core laboratory at Brigham and Women's Hospital performed analysis using methods previously described. 23 
Physical Activity
At baseline, all participants were asked, "What has the subject's usual pattern of exercise been during the past 2 weeks?" for 3 categories of activity: heavy (eg, jogging, tennis, strenuous gardening, or housework), medium (brisk walking, moderate gardening, or housework), and light (slow walking). Subjects provided the number of times per week and number of minutes each time for each category of PA; the product of these values was calculated to provide the number of minutes per week of each category of activity. Heavy activity was classified as vigorous activity, and medium activity was classified as moderate activity. Although not formally validated, the questions represent the American College of Sports Medicine descriptors of light, moderate, and vigorous activity and corresponding metabolic equivalents from the Compendium of Physical Activities. 24, 25 These questions also resemble those validated in other cohort studies such as the Women's Health Initiative and the Behavioral Risk Factor Surveillance System Questionnaire.
26,27
Clinical Perspective
What Is New?
• Although it is well known that physical activity is inversely associated with adverse cardiovascular outcomes in healthy populations, the impact of physical activity in patients with heart failure (HF) with preserved ejection fraction (HFpEF) is less well characterized.
• These findings demonstrate that low levels of physical activity among stable patients with HFpEF are associated with a higher risk of adverse outcomes, including HF hospitalization and cardiovascular mortality.
• Subjects with American Heart Association-recommended poor and intermediate activity exhibit a similarly increased risk of adverse outcomes compared with those with ideal activity.
What Are the Clinical Implications?
• In patients with HFpEF, several studies have demonstrated the ability of exercise training to improve cardiorespiratory fitness and quality of life but have yet to show a clear benefit in reducing hospitalizations or mortality.
• Lifestyle modification with physical activity or exercise training may be one way to modify the adverse cardiovascular outcomes and mortality associated with HFpEF.
• Findings support the need for future prospective randomized studies to evaluate the role of physical activity, including the appropriate dose and type of exercise, on outcomes in patients with HFpEF.
Minutes per week of moderate or vigorous activity was converted to intensity categories of PA (poor, intermediate, and ideal) as defined by the American Heart Association (AHA) because of the skewness of the variable. 2 Ideal PA was defined as ≥150 min/wk of moderate activity, ≥75 min/wk of vigorous activity, or ≥150 min/wk of moderate plus vigorous activity. Intermediate PA was defined as 1 to 149 min/wk of moderate activity, 1 to 74 min/wk of vigorous activity, or 1 to 149 min/wk of moderate plus vigorous activity. Poor PA was defined as 0 min/wk of moderate plus vigorous activity.
Finally, total PA per week was assessed in terms of metabolic equivalents (METs) in MET-minutes per week by equating heavy-, medium-, and light-intensity activity into the low end of their MET equivalents as 6, 3, and 1 MET, respectively, and multiplying by the duration of activity per week; the sum of MET-minutes per week of PA at each intensity level were combined to give the total amount of PA per week. 24, 28 
Statistical Analysis
Descriptive statistics for the study population by PA category are presented as mean±SD, proportion, or median (interquartile range) for skewed variables. Tests for trend were based on linear regression, χ 2 trend tests, and the Cuzick nonparametric trend tests. 29 A 2-sided value of P<0.05 was considered statistically significant.
We related AHA-assigned PA category at baseline to the primary outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest) using a Kaplan-Meier survival curve. We also related baseline PA category to the primary outcome, its components, all-cause mortality, and all-cause hospitalization using a multivariable Cox proportional hazards model. Assessment of the proportional hazards assumption was performed with Schoenfeld residuals using linear, logtransformed, and rank-transformed time scaling. 30 In addition, analysis was repeated with a binary activity variable of ideal versus nonideal PA with results provided in the onlineonly Data Supplement.
Variables in the Cox models included variables thought to be important confounders a priori (age, sex, race, treatment group, enrollment strata, previous myocardial infarction [MI] , previous HF hospitalization, previous cerebrovascular accident [CVA], LVEF, smoking status, alcohol use, creatinine, hemoglobin, β-blocker use).
19,31-34 Model 1 adjusted for basic demographics: age, sex, white race, treatment group, and enrollment strata. Model 2 adjusted for additional confounders: previous MI, previous HF, previous CVA, LVEF, smoking status, alcohol use, creatinine, hemoglobin, and β-blocker use. Model 3 considered the contribution of additional potential mediators: New York Heart Association (NYHA) class, diabetes mellitus, systolic blood pressure, body mass index (BMI), chronic obstructive pulmonary disease, and heart rate.
We also related deciles of total PA in MET-minutes per week to the incidence rate (per 100 person-years) of the primary outcome.
Those with missing PA data (n=18) were omitted from the analysis. Additional sensitivity analyses were performed to evaluate the validity of the results; results from repeated analyses excluding those with various comorbidities are available in the online-only Data Supplement. Finally, evaluation included testing for interaction between PA and age, sex, BMI, and treatment.
Of the 935 echocardiographic studies performed, 643 studies remained for analysis after the exclusion of subjects not in the Americas region and with missing PA data (n=11). Descriptive statistics for this subset are also presented.
All statistical analyses were performed with Stata Software (version 13, Stata Corp., College Station, TX).
RESULTS
Baseline characteristics of participants by PA category are shown in Table 1 . Those with poor PA were more likely to be women and enrolled in the trial by the HF hospitalization entry criteria rather than BNP entry criteria. The majority of subjects were classified as having NYHA class II HF, including those with poor PA. Although those with NYHA class III HF were more likely to have poor PA levels, ≈20% demonstrated baseline activity levels consistent with ideal PA (Figure 1 ).
Subjects with ideal PA were less likely to have diabetes mellitus, chronic kidney disease, and history of prior HF hospitalization and demonstrated lower BMI, resting heart rate, hemoglobin, and creatinine. There was no significant difference in LVEF or the prevalence of hypertension, insulin use, history of myocardial infarction, history of stroke, atrial fibrillation, or chronic obstructive pulmonary disease by PA category.
The median follow-up time was 2.4 years. The primary composite outcome occurred in 519 patients (397 HF hospitalizations, 222 cardiovascular deaths, and 6 aborted cardiac arrests). Time to primary outcome (logrank test, P=0.003; Figure 2A ) and time to first HF hospitalization (log-rank test, P=0.003; Figure 2B ) were significantly different by PA category, whereas there was no significant difference in cardiovascular mortality by PA category (log-rank test, P=0.13; Figure 2C ).
Testing for proportional hazards demonstrated a significant interaction between baseline PA and time since randomization (Table IA in the online-only Data Supplement), such that the associations between PA and outcomes were much stronger with closer proximity to randomization. As a result, all subsequent analyses were truncated at 2 years after randomization with no residual interaction detectable over this time interval (Table IB in 
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Time to primary outcome, first HF hospitalization, and cardiovascular mortality are significantly different by PA category over the first 2 years ( Figure I in the onlineonly Data Supplement). In analyses beginning 2 years after randomization, no relationships were found between PA and subsequent outcomes. Cox proportional hazards results for the full duration of the study are provided in the online-only Data Supplement, including additional results accounting for the proportional hazards violation with baseline PA modeled with timevarying coefficients (Table II in the online-only Data  Supplement) . Again, the associations between PA and outcomes remained significant in the first 2 years with no association with outcomes in subsequent years.
Compared with those with ideal baseline PA, poor PA was associated with a greater risk of the primary outcome (hazard ratio [ Data are reported as n (%), mean±SD, or median (interquartile range) as appropriate. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; KCCQ (QOL), Kansas City Cardiomyopathy Questionnaire (Quality of Life); and NTproBNP, N-terminal pro-B-type brain natriuretic peptide.
*Among those enrolling via brain natriuretic peptide stratum. In the overall study, the study-qualifying brain natriuretic peptide or NT-proBNP values were reported in 88.5% patients enrolled in this stratum; values were not collected for 11.5% who were enrolled before a change to the enrollment form was implemented in August 2007.
(Continued ) (Table 2 ), yet the relationship between PA and the primary outcome remained significant. A linear trend was also present such that those with the least activity (poor PA) demonstrated the highest risk of the primary composite outcome, HF hospitalization, cardiovascular mortality, and all-cause mortality (for linear trend, all P≤0.02); however, the magnitude of risk in those with intermediate and poor activity was similar. A pooled comparison of nonideal versus ideal activity is presented in Table III in the online-only Data Supplement.
Evaluation of total PA per week (MET-minutes per week) as a continuous measure that also accounted for the amount of light-intensity activity per week demonstrated a median total activity level of 60 MET-min/wk (interquartile range, 0-240 MET-min/wk) among all subjects. Total activity levels less than the AHA-recommended 500 METmin/week of activity were associated with a higher risk of the primary outcome (HR, 1.67; 95% CI, 1.14-2.46) and HF hospitalization (HR, 1.77; 95% CI, 1.14-2.74) but not cardiovascular mortality (HR, 1.97; 95% CI, 0.95-4.07).
Evaluation of incidence rates revealed a markedly lower risk of the primary outcome in those who achieved >350 MET-min/wk of activity (Figure 3) .
Repeat analysis of the relationship of PA with the primary outcome yielded similar results after the exclusion of those with previous MI and CVA as comorbidities 
that may be associated with a decline in activity; however, results are limited by fewer events in this subset (Table IV in the online-only Data Supplement). There was no significant interaction between PA and age, sex, or BMI. A marginally significant interaction (P=0.04) was present between PA category and treatment, such that poor activity may be associated with higher risk of the primary outcome and HF hospitalization in those who received placebo. However, this analysis is limited by the occurrence of <20 events in the ideal PA group (Table V in the online-only Data Supplement).
Baseline characteristics of subjects who participated in the echocardiographic substudy represent a different population from the overall Americas sample with a significantly higher prevalence of MI and lower prevalence of atrial fibrillation in those with ideal activity (Table VI in the online-only Data Supplement). In this subset with echocardiographic parameters, including LVEF, diastolic function, E/e', LV hypertrophy, LV mass index, and left atrial volume index were not significantly different between activity groups. Tricuspid regurgitation velocity was marginally significantly higher in those with poor activity.
DISCUSSION
This post hoc analysis demonstrates that in patients with HFpEF, poor and intermediate baseline PA compared with ideal PA was associated with a 2-fold higher risk of HF hospitalization and mortality. Moreover, although risk remains high at lower levels of activity, near-ideal baseline PA levels (>350 MET-min/wk) are associated Adjusted hazard ratios for multiple trial outcomes calculated with the use of Cox proportional-hazards model. *Model 1 was adjusted for age, sex, white race, treatment group, and enrollment strata. †Model 2 represents model 1 plus previous myocardial infarction, previous heart failure hospitalization, previous cerebrovascular accident, left ventricular ejection fraction, smoking status, alcohol use, creatinine, hemoglobin, and β-blocker use. ‡Model 3 represents model 2 plus New York Heart Association class, diabetes mellitus, systolic blood pressure, body mass index, heart rate, and chronic obstructive pulmonary disease.
with a lower risk of HF hospitalization and mortality in this population. These associations were strongest in the first 2 years after baseline activity assessment.
With a rising prevalence, HFpEF is responsible for substantial morbidity and mortality, accounting for ≈50% of HF hospitalizations. [35] [36] [37] [38] [39] Patients with HFpEF are typically older and burdened with multiple comorbidities, including obesity, hypertension, chronic kidney disease, and diabetes mellitus. [37] [38] [39] [40] Despite the heterogeneous phenotype among patients with HFpEF, they commonly present with symptoms of exercise intolerance. 15 The impact of PA, which may reflect a component of exercise tolerance and overall health status, on relevant clinical end points such as HF hospitalization and mortality in this population has not yet been demonstrated. [8] [9] [10] [11] [12] [13] In this study, we have extended previous findings by showing a favorable association between baseline PA and reduced HF hospitalizations and mortality risk in a large HFpEF cohort. Furthermore, this association was strongest within the first 2 years of baseline activity assessment, suggesting that the impact of PA changes over time.
There was no significant association between PA and all-cause hospitalization, suggesting a specific effect of PA on HF hospitalizations. With fewer hospitalizations for HF, ideal PA may play an important therapeutic role in reducing adverse cardiovascular outcomes. The echocardiographic substudy in TOPCAT represents a limited sample and thus limits conclusions related to the role of cardiac structure and function in this analysis. Still, the mechanism by which baseline PA may lower risk of adverse outcomes may be related to better indices of diastolic function associated with more active participants as demonstrated in cohort studies. 41, 42 Alternatively, peripheral mechanisms such as improvements in skeletal muscle function may play a role. In a study of 40 stable outpatients with HFpEF, half of whom participated in 4 months of endurance exercise training, peak oxygen consumption (Vo 2 ) was higher in the intervention group. Mediation analysis demonstrated that this was attributed primarily to increased peak arterial-venous oxygen difference, suggesting that improvements in either skeletal muscle function or microvascular function may be responsible. 43 In this post hoc analysis, we focused on patients from the Americas region because this group represents a population more consistent with the diagnosis of HFpEF as demonstrated by the ≈4-fold higher event rates compared with those in Russia and Georgia. 22 Secondary analysis of the primary study demonstrated a reduction in the primary outcome, HF hospitalization, and cardiovascular mortality in those receiving spironolactone in the Americas region. After this treatment effect was accounted for with multivariable adjustment, greater baseline PA remained significantly associated with better outcomes in this population, including fewer HF hospitalizations. Interaction testing suggests a slightly stronger treatment effect in less active patients; however, this analysis should be interpreted cautiously because it is limited by the occurrence of few events in those with ideal PA. Spironolactone has recently been associated with increased exercise tolerance (peak Vo 2 ) in patients with HFpEF and an abnormal diastolic response to exertion. 44 Pooled data suggest that therapy with mineralocorticoid-receptor antagonists is associated with an improvement with diastolic function rather than changes in LV structure or mass. 45 This raises the question of whether spironolactone may reduce HF hospitalizations by improving diastolic function and exercise tolerance in those who are less active at baseline. Further studies are certainly needed to elucidate the mechanism.
Although analysis of PA by AHA categories suggested a small dose-response relationship, those with poor and ORIGINAL RESEARCH ARTICLE intermediate baseline PA appear to have a similar magnitude of increased risk of adverse cardiovascular outcomes compared with those with ideal PA. Notably, the doseresponse relationship between increasing PA categories and risk of HF hospitalization dissipates in the most adjusted model that accounts for potential mediators. The absence of a significant dose-response relationship for HF hospitalization suggests that the dose should be evaluated more closely; perhaps there may be a threshold effect, or doses greater than those recommended by the AHA may be required to achieve additional HF hospitalization risk reduction as noted in prospective cohort studies. 3 Still, the risk of HF hospitalization remains significantly higher for those not achieving ideal levels of activity.
Additional analysis of total PA, including light-intensity activity, demonstrated that levels less than the AHArecommended 500 MET-min/wk remained significantly associated with an increased risk of HF hospitalization and mortality. Further evaluation of incidence rates of the primary outcome in relation to increasing deciles of total PA suggests that risk remains high for those with low levels of activity; however, >350 MET-min/wk of activity was associated with lower risk. Prospective studies are needed to further examine this relationship and to identify whether a threshold effect is indeed present.
Because baseline PA in this post hoc analysis may reflect overall health status, attempts to exclude significant comorbidities and to evaluate a population with similar overall health status in the sample showed a consistent magnitude and direction in the findings. Even after the exclusion of those with a baseline history of MI and CVA from the analysis, a significantly increased risk of the primary outcome and HF hospitalizations was present in those with poor and intermediate baseline PA. Furthermore, ≈20% of those who achieved ideal PA levels were classified as having NYHA class III HF, suggesting that many class III patients are able to achieve ideal levels of PA. Alternatively, the subjectivity inherent in NYHA classification may not fully account for the true functional limitations or activity patterns in patients with HFpEF as reflected by PA assessment.
An effective therapy for patients with HFpEF remains elusive since large randomized trials have yet to show a mortality benefit with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or mineralocorticoid-receptor antagonists. [16] [17] [18] [19] Lifestyle modification with PA may be one way to modify the adverse cardiovascular outcomes associated with HFpEF. A number of studies have demonstrated the ability of exercise training to improve cardiorespiratory fitness and quality of life in these patients but have yet to show a clear benefit in reducing hospitalizations or mortality. [8] [9] [10] [11] [12] [13] The question remains whether exercise training would improve clinical outcomes in patients with HFpEF. This has been previously examined in patients with HF with reduced ejection fraction in a large, randomized trial in which subjects were randomized to usual care with or without exercise training, yet it demonstrated a nonsignificant reduction in the primary end point of all-cause mortality or hospitalization and only a borderline effect after adjustment for highly prognostic baseline characteristics. 46 Subjects also had nearly perfect adherence to guideline-directed medical therapy, which may have affected the lack of significant difference demonstrated between the 2 groups. Furthermore, adherence to exercise is notoriously difficult to maintain and ascertain. In contrast, guidelinedirected therapy does not yet exist for those with HFpEF, and the impact of exercise training on clinical outcomes in this population remains unknown. The heterogeneous population comprising those with HFpEF may limit the ability to identify those in whom PA may carry a stronger association with outcomes or those who may benefit from exercise training. Identifying the appropriate exercise-training regimen and defining a specific population will be critical to understanding the impact of PA in this population. The findings from this post hoc analysis support the need for randomized controlled studies to evaluate whether exercise training is an effective therapy in improving outcomes in patients with HFpEF.
The strengths of this study relative to other studies in patients with HFpEF include its large size, long-term follow-up, and evaluation of cardiovascular outcomes associated with PA. Several limitations of this post hoc analysis should also be noted. PA was evaluated only at baseline, and self-reported measures of PA are subject to recall bias and may not be representative of cumulative activity or fitness levels; more validation studies are needed. [47] [48] [49] The dissipation of the relationship between baseline PA and outcomes in the first 2 years may limit generalizability of outcomes beyond 2 years. Baseline PA may instead act as a surrogate for overall health status, which is subject to frequent changes with incident events. Once an event or change in clinical status occurs, baseline PA may no longer reflect subsequent risk of adverse outcomes in a population with high morbidity and mortality. Despite adjusting for multiple confounders, we cannot rule out the possibility of unmeasured residual confounding. Moreover, conclusions about causality also cannot be made in this post hoc analysis. Additional analysis to exclude those with baseline comorbidities revealed consistently increased risk of the primary outcome in those with poor baseline PA; however, effect estimates have large CIs, likely resulting from the marked reduction in the number of events after the exclusion of those with MI and CVA.
CONCLUSIONS
We found that in patients with HFpEF, both poor and intermediate baseline PA was associated with a 2-fold increased risk of HF hospitalization and mortality. In par-ticular, risk remains high for lower amounts of total PA until values near AHA-recommended levels are achieved. Prospective studies are needed to confirm the direction and magnitude of this association, to determine whether a threshold effect is present, and to identify if and which type of exercise interventions are effective in reducing adverse cardiovascular outcomes in those with HFpEF.
